Authors

Latest:

Dr. Nikiforov on Reclassifying Subtype of Thyroid Cancer

Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Yvonne Lin, MD, MS

Latest:

Immunotherapy Examined as Treatment Option in Locally Advanced Cervical Cancer

The notion of commandeering the immune system to treat cancer actually dates back more than a century with intratumoral bacterial injections to try and elicit tumor regression.

Yvonne M. Saenger, MD

Latest:

Dr. Saenger on the Need for Immunotherapy Biomarkers

Yvonne M. Saenger, MD, Assistant Professor in Medicine and Dermatology, Hematology and Medical Oncology, Mount Sinai School of Medicine, discusses the need for biomarkers for immunotherapies.

Yvonne N. Fondufe-Mittendorf, PhD

Latest:

University of Kentucky Lab Seeks to Decode Epigenetic Signals in Cancer

Although many labs study cancer as an all-or-nothing process, putting all metastable hybrid stages in the same bin, our laboratory at the University of Kentucky is exploring carcinogenesis as a continuum, from initiation through progression to maintenance. This approach has prompted us to focus on the role of epigenetics in cancer development.

Yvonne Saenger, MD

Latest:

Dr. Saenger on Immunotherapy Combinations in Melanoma

Yvonne Saenger, MD, director of Melanoma Immunotherapy at Columbia University Medical Center, discusses immunotherapy combinations in melanoma.

Yvonne Weideman, DNP, MBA, RN, CNE

Latest:

Matching Ostomy Pouching Systems to Patient Need

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

Zachariah DeFilipp, MD

Latest:

Safety and Efficacy of Axatilimab in Patients With Chronic Graft-Versus-Host Disease (AGAVE-201)

Zachariah DeFilipp, MD, presents data from AGAVE-201, a phase 2, open-label, randomized, multicenter study evaluating axatilimab at 3 dose levels in patients with recurrent/refractory chronic graft-versus-host disease (GVHD).

Zachariah M. DeFilipp, MD, Massachusetts General Hospital

Latest:

Updates in the Management of Graft-Versus-Host Disease

Zachary C. Landman, MD

Latest:

Dr. Landman on Delivering Value-Based Care to Patients

Zachary C. Landman, MD, clinical fellow in Orthopedic Surgery, Department of Orthopedic Surgery, Massachusetts General Hospital, discusses the process of delivering value-based care to patients with cancer.

Zachary Hartman

Latest:

Cost Versus Quality in Different Sites of Cancer Care

More oncology providers have shifted toward consolidation of practices to remain viable. In the last 4 years, 524 private practices have entered into agreements with or have been acquired by hospitals.

Zachary S. Morris, MD, PhD

Latest:

Combinations With RT May Improve Immunotherapy Response

One potential approach to improving the response to cancer immunotherapies is to combine such treatments with radiotherapy.

Zahi Mitri, MD

Latest:

Dr. Mitri Discusses the Promise of Trastuzumab Biosimilars

Zahi Mitri, MD, MS, assistant professor of medicine, Oregon Health and Science University, discusses the promise of trastuzumab (Herceptin) biosimilars.

Zahi Mitri, MD, MS

Latest:

HER2-low Breast Cancer: Practical Applications of ADC Therapy

Practical considerations for the sequencing or combination of novel antibody drug conjugates to optimize outcomes for patients with HER2-low breast cancer.

Zarah Dulce F. Lucas, MD

Latest:

From Bedside to Bench

Based on a current laboratory research project, Zarah Dulce F. Lucas, MD, discusses microRNAs and their potential to predict brain metastases in patients with triple-negative and HER2-positive breast cancer.

Zev A. Wainberg, MD

Zev A. Wainberg, MD, MSc, is a professor of medicine in the Department of Medicine at UCLA and co-director of the UCLA GI Oncology Program

Latest:

Ongoing Research to Watch in Advanced Gastric/GEJ Cancer

Yelena Y. Janjigian, MD, and Zev A. Wainberg, MD, discuss ongoing trials that could help refine the gastric/GEJ cancer treatment paradigm.

Zev A. Wainberg, MD, David Geffen School of Medicine at UCLA

Zev A. Wainberg, MD, UCLA Medical Center

Latest:

“GI Talk”: A Review of Data from the ASCO 2020 Virtual Meeting

Zev A. Wainberg, MD, UCLA School of Medicine

Zhaoming Wang, PhD

Latest:

Utility of Genome-Wide Association Studies in Pediatric Oncology

Zhaoming Wang, PhD, bioinformatics scientist, Department of Computational Biology, St. Jude Children’s Research Hospital, discusses the utility of genome-wide association studies in pediatric oncology.

Zhi Zhang Yang, MD

Latest:

Dr. Yang on the Efficacy of Immunotherapy in Follicular Lymphoma

Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.